



carpal tunnel syndrome is mentioned briefly, but it is not defined and its symptoms and treatments are not described.

The presentation of prevalence is indicative of the more pervasive problems with the authors' use of research throughout the book. It is unfortunate that they sensationalize prevalence rather than provide musicians with information based on a careful review of the research literature.

I would argue that a book intended for musicians rather than scientists should still provide references so that musicians do not remain "easy prey." What a disservice to musicians it is to expect them to follow health advice without question. The authors themselves advise the reader to "be an informed customer" and to "ask for outcome statistics"; this is all I am asking of them.

I would not recommend referencing every statement, but references should at least follow sentences beginning "Study after study shows" Admittedly, including references would not remedy the more serious problems that arise when the authors misinterpret or draw erroneous conclusions from the literature. Considering these concerns and the authors' emphasis on back-extension stretches — advice that is given without appropriate cautions — I am unable to recommend this book to physicians or musicians.

**Christine Zaza, ARCT, BMus,
MSc, PhD**

National Cancer Institute of Canada
Postdoctoral Fellow
University of Western Ontario
London, Ont.
Director, Canadian Network for
Health in the Arts

Debating thrombolysis in stroke

The gist of the article by Corinne Hodgson and Kathleen Whelan¹ is that thrombolysis for stroke is a good thing, enthusiastically endorsed by university-based neurologists. The implication is that physicians who practise emergency medicine in the community

are providing suboptimal treatment because of the exigencies of practice away from wonderful academic centres.

The research is not as conclusive as Hodgson and Whelan imply. I am aware of 5 trials of thrombolysis in stroke, only 1 of which showed even modest benefit,² and 4 of which showed harm.³⁻⁶ Furthermore, neurologists and radiologists have demonstrated⁷ that CT scans have only 80% sensitivity in detecting central nervous system bleeding, which is not good enough. Thrombolysis for stroke is a dangerous therapy. It may help a very few selected patients, but it by no means offers the same benefit for stroke as it does for acute myocardial infarction.

Howard L. Bright, MD
Chilliwack, BC

References

- Hodgson C, Whelan K. Are physicians ready for thrombolysis for acute stroke? A qualitative study. *CMAJ* 1998;159(6 Suppl):19S.
- National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. *N Engl J Med* 1995(24):1581-7.
- Hacke W, Kaste M, Fieschl C, Toni D, Lesaffre E, von Kummer R, et al, for the European Cooperative Acute Stroke Study (ECASS) Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. *JAMA* 1995;274(13):1017-25.
- Multicentre Acute Stroke Trial — Italy (MAST-1) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. *Lancet* 1995;346:1509-14.
- Multicenter Acute Stroke Trial — Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. *N Engl J Med* 1996;335(3):145-50.
- Donnan GA, Davis SM, Chambers BR, Gates PC, Hankey GJ, McNeil JJ, et al, for the Australian Streptokinase (ASK) Trial Study Group. *JAMA* 1996;276(12):961-6.
- Schriger DL, Kalafut M, Starkman S, Krueger M, Saver JL. Cranial computed tomography interpretation in acute stroke: physician accuracy in determining eligibility for thrombolytic therapy. *JAMA* 1998;279(16):1293.

[One of the authors responds:]

The question posed in this study was not "should thrombolysis be used?" (an issue best studied in quantitative, clinical research) but rather, "if thrombolysis were to be approved, would physicians in different settings be willing, or have the resources, to use it?" The relevance of this qualitative research is underscored by Health Canada's approval in February 1999 of the use of tissue plasminogen activator for ischemic stroke. Many of the themes explored in theoretical terms in this study (e.g., time to hospital presentation and access to CT scanning) are now real and pressing issues for community-based physicians who may want to take advantage of this new therapy.

As noted in the article, thrombolysis should be viewed as only a part (probably a relatively small part) of good stroke management.

Corinne Hodgson, MA, MSc

Corinne S. Hodgson & Associates Inc.
Pelham, NH

Correction

Part of a sentence was inadvertently dropped from a recent article.¹ The sentence should have read: "When Dr. Parsons tried giving the babies irradiated ergosterol instead of cod liver oil there was a dramatic improvement, and the ward sister met us at the door and said, 'You've got it.'" We apologize for this error.

Reference

- Brooks J. Alberta physician made a career of roughing it in the bush. *CMAJ* 1999;160:701-2.

Submitting letters

Letters may be submitted by mail, courier, email or fax. They must be signed by all authors and limited to 300 words in length. Letters that refer to articles must be received within 2 months of the publication of the article. *CMAJ* corresponds only with the authors of accepted letters. Letters are subject to editing and abridgement.

Note to email users

Email should be addressed to pubs@cma.ca and should indicate "Letter to the editor of *CMAJ*" in the subject line. A signed copy must be sent subsequently to *CMAJ* by fax or regular mail. Accepted letters sent by email appear in the Readers' Forum of *CMA Online* (www.cma.ca) promptly, as well as being published in a subsequent issue of the journal.